Transitional Cell Carcinoma (Urothelial Carcinoma): Symptoms, Diagnosis, Stages & Treatment

Transitional cell carcinoma (TCC) is the older name for what is now generally called urothelial carcinoma (UC) — a cancer arising from the urothelium, the specialized tissue lining the urinary tract. These aren’t two different diseases; TCC and urothelial carcinoma refer to the same cancer, and “urothelial carcinoma” is the term now preferred in current medical literature and guidelines. Because many patients still encounter “transitional cell carcinoma” on pathology reports or in search results, this guide uses both terms, but relies on “urothelial carcinoma” as the modern standard.

The urothelium lines the renal pelvis (part of the kidney), the ureters (tubes connecting kidneys to bladder), the bladder, and part of the urethra. Urothelial carcinoma can arise anywhere along this lining, though the bladder is by far the most common site.

This cancer’s treatment depends heavily on a few key distinctions covered throughout this guide: whether it has invaded the bladder’s muscle layer, whether it’s confined to the bladder or has spread, and whether it arose in the bladder or the upper urinary tract — each of these changes the treatment conversation substantially.

Where Does Urothelial Carcinoma Develop?

The bladder is the most common site for urothelial carcinoma. When it develops in the renal pelvis or ureter instead, it’s called upper tract urothelial carcinoma (UTUC) — a meaningfully different clinical situation requiring its own treatment approach. It can also, less commonly, occur in the urethra.

Not every cancer found in the urinary tract is urothelial carcinoma — other histologic types occur in the bladder specifically, discussed below.

Urothelial carcinoma vs. other bladder cancer types:

Treatment approaches can differ meaningfully by histology, which is exactly why an accurate pathology diagnosis — not just “bladder cancer” as a general label — matters for treatment planning.

Non-Muscle-Invasive vs. Muscle-Invasive Disease

This is the single most important distinction in bladder urothelial carcinoma. Non-muscle-invasive bladder cancer (NMIBC) is confined to the inner layers of the bladder wall; muscle-invasive bladder cancer (MIBC) has grown into the muscular wall itself. Treatment strategy changes dramatically once muscle invasion occurs.

Roughly the majority of bladder urothelial carcinoma is diagnosed at the non-muscle-invasive stage — but NMIBC is not simply “early bladder cancer” to be dismissed lightly; it carries a real, individualized risk of recurrence and, in higher-risk cases, progression to muscle-invasive disease, which is exactly why risk-based management (discussed below) matters.

Papillary Tumors vs. Carcinoma in Situ

Within NMIBC specifically, there are two distinct growth patterns worth understanding:

• Papillary tumors — grow in a finger-like projection into the bladder’s hollow interior (lumen). These are often visible directly during cystoscopy as a distinct mass.
• Carcinoma in situ (CIS) — a flat, high-grade form of urothelial carcinoma. CIS doesn’t form an obvious mass, which can make it harder to detect visually, but it’s considered clinically significant and aggressive despite its flat appearance — it’s not a “milder” form of the disease simply because it’s flat rather than raised.

It’s important not to confuse CIS with invasive cancer: CIS is, by definition, non-invasive (confined to the surface lining), but it behaves aggressively and carries meaningful risk of progression if not properly treated — which is why its presence specifically affects risk stratification and treatment decisions, discussed further below.

Grade vs. Stage — A Crucial Distinction

Grade and stage describe two different things, and confusing them is one of the most common misunderstandings patients have. Stage describes how far the cancer has spread (from confined to the bladder lining, to invading muscle, to spreading to lymph nodes or distant organs). Grade describes how abnormal the cancer cells look under the microscope — essentially, how aggressive the tumor’s biology appears.

• Low-grade urothelial carcinoma — cells appear closer to normal, generally associated with slower growth and a lower (though not zero) risk of progression
• High-grade urothelial carcinoma — cells appear more abnormal, associated with a higher risk of recurrence, progression, and, in the case of muscle-invasive disease, spread

A tumor’s stage and grade are assessed together, but they’re independent pieces of information — a low-stage tumor can still be high-grade, and this combination genuinely matters for treatment planning, particularly within NMIBC risk stratification.

Symptoms

The most common and important warning symptom is blood in the urine (hematuria) — particularly when it’s visible, painless, and unexplained. Other symptoms can include urinary frequency, urgency, and burning, though these overlap significantly with far more common, non-cancerous conditions like urinary tract infections.

Common symptoms:

• Blood in the urine — visible as pink, red, or cola-colored urine, or detected only on urine testing
• Increased urinary frequency
• Urinary urgency
• Burning or pain during urination
• Pelvic discomfort

Symptoms more associated with advanced disease:

• Flank pain (particularly relevant to upper tract disease)
• Difficulty urinating
• Unintentional weight loss
• Bone pain
• Fatigue
• Leg swelling
• Other symptoms related to the specific site of any distant spread

A genuinely important point: painless, visible blood in the urine is one of the more important warning signs for bladder cancer specifically, and should prompt evaluation even if it occurs only once and resolves on its own. That said, hematuria does not always mean cancer — infections, kidney stones, and other benign conditions are far more common causes of blood in the urine. The point of mentioning this symptom prominently is to encourage evaluation, not to suggest that everyone who notices blood in their urine has cancer.

Upper tract symptoms specifically can include hematuria, flank pain, and urinary obstruction — and it’s worth noting that some upper tract tumors are discovered incidentally, during imaging done for an unrelated reason, before symptoms appear at all.

Causes and Risk Factors

Cigarette smoking is the single strongest, most well-established preventable risk factor for bladder urothelial carcinoma. Occupational chemical exposure, prior pelvic radiation, and certain chronic urinary tract conditions also contribute.

On smoking specifically: tobacco-related chemicals are filtered through the kidneys and concentrated in urine, directly exposing the bladder lining over years of smoking. Risk remains somewhat elevated in former smokers compared to people who never smoked, though quitting does reduce risk over time — this is worth saying plainly for anyone who has already quit and is wondering whether it “still matters”: it does, meaningfully, even if it can’t fully erase prior risk.

On occupational exposure: certain industries carry documented associations with increased urothelial carcinoma risk due to aromatic amine exposure, but this doesn’t mean every chemical exposure in every workplace carries equivalent risk — the association is specific to certain compounds and exposure levels, not a blanket concern about industrial work in general.

Importantly, not every risk factor applies equally to bladder and upper tract disease — for example, some occupational and genetic associations are more strongly linked to one location than the other.

How Urothelial Carcinoma Is Diagnosed

Diagnosis usually involves urine tests, imaging, cystoscopy, and tissue examination. Urinalysis can detect blood but cannot confirm cancer, while urine cytology is particularly useful for detecting high-grade disease and carcinoma in situ.

Cystoscopy allows direct examination of the bladder, while TURBT removes suspicious tumors and provides tissue for definitive diagnosis, grading, and staging.

Pathology and Staging

Pathology assesses tumor type, grade, depth of invasion, muscle involvement, CIS, lymphovascular invasion, and variant histology such as micropapillary or plasmacytoid patterns.

Bladder urothelial carcinoma is staged using the TNM system, with T2 marking invasion into the bladder muscle and higher stages indicating deeper local or distant spread. Upper tract urothelial carcinoma follows different staging criteria.

NMIBC Treatment

Treatment depends on risk category, based on stage, grade, tumor size and number, CIS, recurrence history, and other features.

• Low-risk: TURBT, often followed by immediate intravesical chemotherapy and surveillance.
• Intermediate-risk: TURBT followed by intravesical chemotherapy or BCG in selected cases.
• High-risk: TURBT followed by BCG-based treatment and close surveillance.
• Very-high-risk: Early discussion of radical cystectomy may be appropriate.

BCG Therapy

BCG is an intravesical immunotherapy used mainly for high-risk NMIBC. It is given directly into the bladder through a catheter. Urinary irritation and flu-like symptoms are common, while serious infection is uncommon but requires prompt medical attention.

Muscle-Invasive Bladder Cancer

Curative treatment generally involves perioperative systemic therapy followed by radical cystectomy. Selected patients may instead undergo trimodality therapy, combining maximal TURBT, radiation, and chemotherapy to preserve the bladder.

After cystectomy, urinary reconstruction may involve an ileal conduit, continent diversion, or orthotopic neobladder, depending on the patient’s health, kidney function, tumor location, and anatomy.

Advanced and Metastatic Disease

For eligible patients with previously untreated locally advanced or metastatic urothelial carcinoma, enfortumab vedotin plus pembrolizumab is an important current first-line treatment option. Platinum-based chemotherapy remains relevant for patients who are not suitable for this combination.

Other treatments may include immunotherapy, antibody-drug conjugates, and FGFR-directed therapy such as erdafitinib for tumors with appropriate FGFR alterations.

Upper Tract Urothelial Carcinoma

UTUC affects the renal pelvis or ureter and requires a somewhat different treatment approach. Higher-risk disease is often treated with radical nephroureterectomy, while kidney-sparing procedures may be considered for selected low-risk tumors or patients where preserving kidney function is particularly important.

Prognosis and Follow-Up

Prognosis depends on stage, grade, CIS, lymph node involvement, tumor biology, treatment response, and recurrence. NMIBC requires regular surveillance, particularly with cystoscopy, while patients treated for advanced disease require ongoing imaging and monitoring for recurrence and treatment-related effects.

Treatment Cost in India

The cost of urothelial carcinoma treatment in India varies significantly depending on the cancer stage, location, treatment approach, and duration of therapy. Approximate ranges include:

For advanced or metastatic urothelial carcinoma, treatments such as enfortumab vedotin, pembrolizumab, or FGFR-directed therapy can significantly increase the overall cost, particularly when multiple treatment cycles are required.

These are approximate figures and may vary between hospitals, cities, treatment protocols, and individual patient requirements. A personalized estimate based on the patient’s pathology, stage, and treatment plan is recommended for accurate budgeting..

Considering India for Treatment

India has specialized centers offering urologic oncology, TURBT, BCG, robotic and open surgery, urinary reconstruction, radiation therapy, systemic treatment, and molecular testing. Patients should compare centers based on experience with their specific cancer type, availability of recommended treatments, multidisciplinary care, and follow-up support.

International Patient Treatment Journey

1. Share medical reports — pathology, imaging, prior treatment history
2. Review of CT/MRI and pathology by the receiving oncology team
3. Confirmation of diagnosis as urothelial carcinoma
4. Determination of bladder vs. upper urinary tract origin
5. Establishing grade and stage, including NMIBC vs. MIBC where applicable
6. Review of biomarker/molecular testing, where indicated for treatment planning
7. Multidisciplinary treatment plan development
8. Cost estimate, based on your specific plan
9. Medical visa guidance
10. Travel and accommodation planning
11. Treatment initiation
12. Monitoring of response and side effects
13. Ongoing surveillance
14. Management of recurrence, if it occurs
15. Follow-up coordination after returning home

This process cannot guarantee cure, bladder preservation, exact treatment duration, exact cost, treatment response, survival, visa approval, or specific hospital outcomes — no legitimate source can guarantee any of these.

Questions to Ask Your Urologic Oncology Team

• Is my tumor confirmed as urothelial carcinoma specifically?
• Is it located in the bladder or the upper urinary tract?
• What is the grade — low or high?
• Is it non-muscle-invasive or muscle-invasive?
• Is carcinoma in situ present?
• What is my specific TNM stage?
• Are my lymph nodes involved?
• Has the cancer spread elsewhere?
• Do I need a repeat TURBT to confirm staging?
• Am I a candidate for BCG, and what would the schedule look like?
• If I’ve had BCG, is my disease now considered BCG-unresponsive?
• Should I consider radical cystectomy, or am I a candidate for bladder preservation?
• Am I eligible for cisplatin-based chemotherapy?
• Is immunotherapy or the enfortumab vedotin/pembrolizumab combination appropriate for my situation?
• Should molecular or FGFR testing be performed in my case?
• What is my realistic recurrence risk based on my specific pathology?
• What will my surveillance schedule look like going forward?

Frequently Asked Questions

Where This Leaves You

Being told you have “transitional cell carcinoma” or “urothelial carcinoma” can feel disorienting, especially with two different names for the same disease. The most important things to take from this guide: whether your disease is non-muscle-invasive or muscle-invasive changes everything about treatment; upper tract disease is genuinely different from bladder disease; and the treatment landscape for advanced disease has changed substantially in recent years, with modern immunotherapy-based combinations now standard where they weren’t even a few years ago.

If you’re evaluating treatment options, including treatment in India, sharing your pathology report, imaging, and any prior treatment history is the most useful first step toward an accurate, individualized picture of your specific situation — far more useful than any generic statistic or cost figure. Shifam Health can help coordinate that record review, hospital and specialist selection, treatment cost estimates, and medical visa guidance — while the actual diagnosis, staging, and treatment decisions remain with your urologic oncology team.